A new trading day began on Tuesday, with Pacific Biosciences of California Inc (NASDAQ: PACB) stock price up 6.79% from the previous day of trading, before settling in for the closing price of $2.21. PACB’s price has ranged from $0.85 to $2.72 over the past 52 weeks.
During the last 5-year period, the sales drop of Healthcare Sector giant was -23.55%. Meanwhile, its annual earnings per share averaged -64.82%. With a float of $270.83 million, this company’s outstanding shares have now reached $301.85 million.
Pacific Biosciences of California Inc (PACB) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Medical Devices Industry. The insider ownership of Pacific Biosciences of California Inc is 10.29%, while institutional ownership is 52.56%. The most recent insider transaction that took place on Aug 18 ’25, was worth 35,182. In this transaction an insider of this company sold 26,836 shares at a rate of $1.31, taking the stock ownership to the 1,920,035 shares. Before that another transaction happened on Aug 18 ’25, when Company’s Officer proposed sale 26,836 for $1.31, making the entire transaction worth $35,174.
Pacific Biosciences of California Inc (PACB) Earnings and Forecasts
In its latest quarterly report, released on 12/31/2024, the company reported earnings of -0.2 per share, which was $0.1 lower than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.13 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -64.82% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 25.39% during the next five years compared to -23.55% drop over the previous five years of trading.
Pacific Biosciences of California Inc (NASDAQ: PACB) Trading Performance Indicators
Here are Pacific Biosciences of California Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 5.40. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.61.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.18, a number that is poised to hit -0.14 in the next quarter and is forecasted to reach -0.52 in one year’s time.
